View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. CBDepot
19 April 2021

CBDepot and 4MP Cannabidiol Novel Food Applications with the UK Food Standards Agency are Declared Validated and Verified Food Supplements

CBDepot, with Cannabis Pharma and 4MP Technologies as co-applicants, is delighted to announce that its Regulated Product applications RP70 and RP85 have been validated and verified by the UK Food Standards Agency (FSA) and Food Standards Scotland. Twelve secondary food supplementary products linked to the primary dossiers may remain on the UK market for legal sale whilst undergoing the final risk assessment period.

CBDepot’s commitment to Novel Food compliance began in early 2016, shortly after the CBDex® brand was launched by Cannabis Pharma. Its EU application NF 2019/1371 was the world’s first cannabidiol (CBD) specific dossier to have reached validation status, which it achieved on 27 March 2020.

On 13 February 2020, the FSA announced that it would allow the UK CBD industry a deadline of 31 March 2021 to submit valid novel food authorisation applications. After 31 March 2021, only products which had been submitted in a valid application with verified products and were on sale on 13 February 2020 would be allowed to remain on the UK market. The authorisation process ensures novel foods meet legal standards, including in the areas of safety and actual CBD content.

In early January 2021, CBDepot filed two Regulated Product applications with the UK FSA in order to grant access for its two grades of CBD to the biggest legal CBD food supplement market worldwide. These were application RP70, for pure CBD with 4MP®-branded secondary products in the forms of carrier oils, measured dose spray and chewable tablets, and application RP85, for isolated CBD and CBDex-branded secondary products in the form of carrier oils linked to this dossier.

“Validated food supplements under the CBDex and 4MP brands may remain on the UK market for legal sale leading up to final authorisation next year,” confirms Boris Baňas, founder and CSO of CBDepot. “CBDepot’s battery of proprietary first and second-tier studies on the genotoxicity, subchronic toxicity and toxicokinetics of CBD, already presented to the UK and EU authorities, give us solid grounds for the future of our UK and EU operations.”

“This is an outstanding joint achievement by CBDepot’s and 4MP’s regulatory, scientific and product development teams,” says Scott Cooper, product and business development director of 4MP Technologies. “Our initial offering of practical premium CBD products will shortly be followed by further ranges of premium quality CBD foods and food supplements.

“With the easing of the UK’s Covid lockdown restrictions for non-essential retail and sports facilities sectors, consumers will soon have ease of access to our product ranges. Working together with Trading Standards and the Home Office, we look forward to executing our 2021 planning to manufacture all our finished products in the UK.”

4MP entered the CBD market in 2017, targeting the sports, wellbeing and wholefood sectors by developing a connoisseur range of CBD oils, powders and wholefood supplements. The synergy with CBDepot to produce pure, premium quality and safe products is cemented in the companies’ respective DNAs.

This product originates from cannabis sativa L derivative and is a whitish to yellowish powder.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology